Clinical Trial Update: A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 randomized non-inferiority trial in relapsing-remitting multiple sclerosis compares ongoing anti-CD20 maintenance therapy with a de-escalation strateg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Anti-CD20 therapy (unspecified maintenance vs de-escalation)

Snippet

Sponsor: University Hospital, Montpellier | Conditions: Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | Phase 3 | Status: NOT_YET_RECRUITING